Immunosuppressive role of semaphorin‐3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Timely negative regulation of the immune system is critical to allow it to perform its duty while maintaining it under tight control to avoid overactivation. We previously reported that the neuronal receptor neuropilin‐1 (NP‐1) is expressed in human lymph nodes. However, the role of NP‐1 interaction with its physiological ligand semaphorin‐3A (Sema‐3A) on immune cells remains elusive. Here we show that Sema‐3A is expressed by activated DC and T cells, and that its secretion in DC/T cell cocultures is delayed. Sema‐3A/NP‐1 interaction down‐modulated T cell activation since addition of Sema‐3A in DC/T cell cocultures dramatically inhibited allogeneic T cell proliferation. More importantly, neutralization by blocking antibodies or by antagonist peptide of endogenous Sema‐3A produced by DC/T cell cocultures resulted in a 130% increase in T cell proliferation. Sema‐3A acted directly on T cells, since it could block anti‐CD3/CD28‐stimulated proliferation of T cells. Finally, immunomodulatory functions of Sema‐3A relied on the blockage of actin cytoskeleton reorganization, affecting TCR polarization and interfering with early TCR signal transduction events such as ZAP‐70 or focal adhesion kinase phosphorylation. Therefore, we propose that Sema‐3A secretion and the resulting NP‐1/Sema‐3A interaction are involved in a late negative feedback loop controlling DC‐induced T cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Moura, I. C. (2004) · Blood · doi:10.1182/blood-2003-07-2440 · Cited by 114
Cited by
Semaphorins and their receptors in immune cell interactions
Suzuki, K., Kumanogoh, A., & Kikutani, H. (2008) · Nature Immunology · doi:10.1038/ni1553 · Cited by 400
Neuropilin 1: function and therapeutic potential in cancer
Chaudhary, B., Khaled, Y. S., Ammori, B. J., & Elkord, E. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1500-0 · Cited by 233
“SEMA3A CUB (a1/a2) extracellular domain Promotes prolonged T cell–DC interaction and T cell activation and IL-10 secretion [14, 25, 87]”
BackgroundInfluentialEmerging Role of Semaphorins as Major Regulatory Signals and Potential Therapeutic Targets in Cancer
Tamagnone, L. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.031 · Cited by 158
“, 2010), whereas others reported that Sema3A signaling inhibits T-cell function (Catalano et al., 2006; Lepelletier et al., 2006; Yamamoto et al., 2008).”
BackgroundNeuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Chuckran, C. A., Liu, C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000967 · Cited by 147
Neuropilin‐1 is not a marker of human Foxp3 + Treg
Milpied, P., Renand, A., Bruneau, J., Mendes‐Da‐Cruz, D. A., Jacquelin, S., Asnafi, V., Rubio, M., MacIntyre, E., Lepelletier, Y., & Hermine, O. (2009) · European Journal of Immunology · doi:10.1002/eji.200839040 · Cited by 136
Self-citation
Metadata
- Authors
- Lepelletier, Y., Moura, I. C., Hadj‐Slimane, R., Renand, A., Fiorentino, S., Baude, C., Shirvan, A., Barzilai, A., & Hermine, O.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2006-06-30
- Volume
- 36
- Issue
- 7
- Pages
- 1782-1793
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1986877868
- Cited by
- 182
- References
- 3
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.